• search
For Quick Alerts
For Daily Alerts

Trial results show significant faster time to clinical improvement with Favipiravir: Glenmark


New Delhi, July 22: Glenmark Pharmaceuticals on Wednesday said Phase 3 clinical trial of antiviral drug Favipiravir in mild to moderate COVID-19 patients demonstrated significant faster time to clinical improvement.

Trial results show significant faster time to clinical improvement with Favipiravir: Glenmark

Results from the Phase 3 trial showed numerical improvements for the primary efficacy endpoint with 28.6 per cent faster viral clearance in the overall population in the Favipiravir plus standard supportive care compared to those in the standard supportive care alone (control arm) , Glenmark said in a statement.

No Amarnath Yatra this year due to coronavirus pandemic; 'Aarti' to be broadcast live

The results also demonstrated 40 per cent faster achievement of 'clinical cure' defined as the physician's assessment of normalization of clinical signs – temperature, oxygen saturation, respiratory rate and cough, it added.

"69.8 per cent of patients in the Favipiravir plus standard supportive care (Favipiravir treatment arm) achieved clinical cure by Day 4, which was statistically significant compared to 44.9 per cent observed in the control arm," the statement said. Among patients who clinically deteriorated and required oxygen support, those receiving Favipiravir had a longer median time to first time use of oxygen of 5 days versus 2 days in the control arm, it added.

    Galwan martyr Colonel Babu's wife appointed Deputy Collector | Oneindia News

    Glenmark's Favipiravir was well tolerated with no serious adverse events or deaths in the Favipiravir treated arm. Adverse events were reported in 26 patients in the Favipiravir treatment arm as compared to six patients in the control arm, it added. However, most adverse events were mild to moderate and none led to drug discontinuation or dosing adjustments, the statement said.

    Serum Institute to begin trials of Oxford's COVID-19 vaccine candidate by Aug-end

    "We are encouraged with the top-line results and these indicate that early treatment with Favipiravir may improve clinical outcomes for mild to moderate patients and could potentially prevent patients from progressing to ARDS and mortality," Glenmark Vice President & Head - Clinical Development, Global Specialty/Branded Portfolio Monika Tandon said.

    On June 20, the company had announced receiving manufacturing and marketing approval from India's drug regulator for Favipiravir for the treatment of mild to moderate COVID-19. The company sells the drug under the brand name FabiFlu at a price of Rs 75 per tablet. Shares of Glenmark Pharmaceuticals settled at Rs 413.70 per scrip on BSE, down 0.13 per cent from its previous close.

    For Daily Alerts
    Get Instant News Updates
    Notification Settings X
    Time Settings
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more